Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its ...

Stoke Therapeutics (STOK) has recently seen its stock climb over 2% in the past month, sparking interest about what might be driving investor optimism. With a year-to-date gain of over 200%, the ...

Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the Hot Growth Stocks to Invest in Now. On October 10, Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on Stoke Therapeutics, Inc.

) has been revised to $28.79 / share. This is an increase of 16.51% from the prior estimate of $24.71 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...

The price trend for Stoke Therapeutics, Inc. (STOK) has been bearish lately and the stock has lost 14.8% over the past week. However, the formation of a hammer chart pattern in its last trading ...

Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Stoke Therapeutics (NasdaqGS:STOK) with a Buy recommendation. Analyst Price Forecast Suggests 101.16% Upside As of ...

The growing energy drinks market has sparked both new entrants into the category and expensive acquisitions. Taking a different approach, a leading cold brew brand seems to be trying to split the ...

In recent trading, shares of Stoke Therapeutics Inc (Symbol: STOK) have crossed above the average analyst 12-month target price of $31.62, changing hands for $33.00/share. When a stock reaches the ...

Located 14 km southwest of Leh in the Ladakh district of Jammu and Kashmir, Stok was the seat of erstwhile rulers of Ladakh. Also renowned for the 14th century Buddhist monastery, Stok attracts lots ...

Stoke Therapeutics, Inc. (STOK) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.